EXEL
Price
$41.59
Change
-$0.19 (-0.45%)
Updated
Jun 13 closing price
Capitalization
11.34B
59 days until earnings call
UTHR
Price
$283.35
Change
-$2.79 (-0.98%)
Updated
Jun 13 closing price
Capitalization
12.78B
46 days until earnings call
Interact to see
Advertisement

EXEL vs UTHR

Header iconEXEL vs UTHR Comparison
Open Charts EXEL vs UTHRBanner chart's image
Exelixis
Price$41.59
Change-$0.19 (-0.45%)
Volume$2.13M
Capitalization11.34B
United Therapeutics
Price$283.35
Change-$2.79 (-0.98%)
Volume$564.44K
Capitalization12.78B
EXEL vs UTHR Comparison Chart
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UTHR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. UTHR commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a StrongBuy and UTHR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (EXEL: $41.59 vs. UTHR: $283.35)
Brand notoriety: EXEL: Notable vs. UTHR: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 70% vs. UTHR: 104%
Market capitalization -- EXEL: $11.34B vs. UTHR: $12.78B
EXEL [@Biotechnology] is valued at $11.34B. UTHR’s [@Biotechnology] market capitalization is $12.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 2 FA rating(s) are green whileUTHR’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 2 green, 3 red.
  • UTHR’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than UTHR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 4 TA indicator(s) are bullish while UTHR’s TA Score has 6 bullish TA indicator(s).

  • EXEL’s TA Score: 4 bullish, 4 bearish.
  • UTHR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, UTHR is a better buy in the short-term than EXEL.

Price Growth

EXEL (@Biotechnology) experienced а -3.35% price change this week, while UTHR (@Biotechnology) price change was -13.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

EXEL is expected to report earnings on Aug 12, 2025.

UTHR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UTHR($12.8B) has a higher market cap than EXEL($11.3B). EXEL has higher P/E ratio than UTHR: EXEL (18.99) vs UTHR (11.29). EXEL YTD gains are higher at: 24.895 vs. UTHR (-19.694). UTHR has higher annual earnings (EBITDA): 1.68B vs. EXEL (844M). UTHR has more cash in the bank: 3.32B vs. EXEL (1.03B). EXEL has less debt than UTHR: EXEL (187M) vs UTHR (200M). UTHR has higher revenues than EXEL: UTHR (2.99B) vs EXEL (2.3B).
EXELUTHREXEL / UTHR
Capitalization11.3B12.8B88%
EBITDA844M1.68B50%
Gain YTD24.895-19.694-126%
P/E Ratio18.9911.29168%
Revenue2.3B2.99B77%
Total Cash1.03B3.32B31%
Total Debt187M200M94%
FUNDAMENTALS RATINGS
EXEL vs UTHR: Fundamental Ratings
EXEL
UTHR
OUTLOOK RATING
1..100
6958
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
3134
SMR RATING
1..100
3245
PRICE GROWTH RATING
1..100
3962
P/E GROWTH RATING
1..100
9373
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UTHR's Valuation (65) in the Pharmaceuticals Other industry is in the same range as EXEL (73) in the Biotechnology industry. This means that UTHR’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Profit vs Risk Rating (31) in the Biotechnology industry is in the same range as UTHR (34) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew similarly to UTHR’s over the last 12 months.

EXEL's SMR Rating (32) in the Biotechnology industry is in the same range as UTHR (45) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew similarly to UTHR’s over the last 12 months.

EXEL's Price Growth Rating (39) in the Biotechnology industry is in the same range as UTHR (62) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew similarly to UTHR’s over the last 12 months.

UTHR's P/E Growth Rating (73) in the Pharmaceuticals Other industry is in the same range as EXEL (93) in the Biotechnology industry. This means that UTHR’s stock grew similarly to EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELUTHR
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
58%
MACD
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
56%
Advances
ODDS (%)
N/A
Bullish Trend 18 days ago
69%
Declines
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 4 days ago
60%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
67%
Aroon
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UTHR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EPRX3.86-0.03
-0.64%
Eupraxia Pharmaceuticals
CNH12.57-0.21
-1.64%
CNH Industrial NV
BRC67.96-1.51
-2.17%
Brady Corp
ERNA2.29-0.08
-3.38%
Ernexa Therapeutics Inc
DAKT13.70-0.55
-3.86%
Daktronics

EXEL and

Correlation & Price change

A.I.dvisor tells us that EXEL and RIGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and RIGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
-0.45%
RIGL - EXEL
29%
Poorly correlated
-3.66%
RVMD - EXEL
28%
Poorly correlated
-1.26%
ACLX - EXEL
28%
Poorly correlated
-0.77%
UTHR - EXEL
28%
Poorly correlated
-0.98%
CGON - EXEL
28%
Poorly correlated
-2.42%
More

UTHR and

Correlation & Price change

A.I.dvisor indicates that over the last year, UTHR has been loosely correlated with DAWN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UTHR jumps, then DAWN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UTHR
1D Price
Change %
UTHR100%
-0.98%
DAWN - UTHR
38%
Loosely correlated
-0.30%
MNKD - UTHR
38%
Loosely correlated
-3.13%
CERO - UTHR
33%
Poorly correlated
-7.12%
TGTX - UTHR
32%
Poorly correlated
-3.64%
GERN - UTHR
32%
Poorly correlated
-3.21%
More